Bristol Myers schizophrenia therapy safe in late-stage trial

Published on 6 Apr 2024 on Seeking Alpha

Bristol Myers' (BMY) schizophrenia drug, KarXT, shows a well-tolerated safety profile and potential...

Read the rest of the article

Start tracking your investments with Statfolio

With the earnings season in full swing, these ten large-cap stocks were the worst performers last...

Benzinga 28 Apr 2024

Bristol-Myers Squibb Company BMY reported an adjusted loss per share of $4.40, narrower than the ...

Benzinga 26 Apr 2024

Bristol-Myers Squibb (BMY) stock fell Thursday amid plans to lay off 2,200 employees as part of a...

Seeking Alpha 25 Apr 2024

Bristol-Myers Squibb (BMY) stock dips even as the company topped consensus with Q1 2024 results, ...

Seeking Alpha 25 Apr 2024

The first-quarter 2024 reporting cycle of the Medical sector is about to pick up pace this week. ...

Zacks via Yahoo Finance 24 Apr 2024

Bristol-Myers Squibb Company BMY is scheduled to report first-quarter 2024 results on Apr 25, bef...

Zacks via Yahoo Finance 22 Apr 2024

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk ...

Simply Wall St. via Yahoo Finance 21 Apr 2024

The FDA has mandated updates to safety information for CAR-T cell therapies due to a severe risk ...

Seeking Alpha 19 Apr 2024

Key Insights Institutions' substantial holdings in Bristol-Myers Squibb implies that they have si...

Simply Wall St. via Yahoo Finance 15 Apr 2024

As we navigate an increasingly complex global landscape, our cohesive strategy, inclusive of our ...

3BL CSRwire 12 Apr 2024